A nurse is reviewing the lab work of a client on a medical-surgical unit who has a new prescription for captopril. Which of the following laboratory values should the nurse identify as the priority to monitor?
Alanine aminotransferase
Thyroid-stimulating hormone
Potassium
Magnesium
The Correct Answer is C
Rationale:
A. Monitoring alanine aminotransferase is important for liver function, but it is not the priority for a client on captopril.
B. Thyroid-stimulating hormone is not directly impacted by captopril and is not the priority lab value to monitor in this context.
C. Potassium is the priority laboratory value to monitor because captopril, an ACE inhibitor, can lead to hyperkalemia (elevated potassium levels), which can cause serious cardiac complications.
D. While magnesium levels are important to monitor, they are not specifically related to captopril therapy as potassium levels are.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is B
Explanation
Rationale:
A. "Cloudy" is not a medication and does not address any adverse effects related to topotecan.
B. Granisetron is an antiemetic medication used to prevent nausea and vomiting, which are common adverse effects of topotecan.
C. Insulin lispro is a rapid-acting insulin used to control blood sugar levels and does not relate to the adverse effects of topotecan.
D. Docusate sodium is a stool softener used to prevent constipation, but it does not specifically address the nausea and vomiting associated with chemotherapy.
E. Prednisone is a corticosteroid that may be used for other indications but is not primarily indicated for treating the nausea and vomiting caused by topotecan.
Correct Answer is B
Explanation
Rationale:
A. Hydrochlorothiazide does not prevent angiotensin II from binding with receptor sites; this action is typically associated with ACE inhibitors or angiotensin receptor blockers.
B. Hydrochlorothiazide decreases the reabsorption of sodium and water in the distal renal tubule, which leads to increased urine output and decreased blood volume, effectively lowering blood pressure.
C. Hydrochlorothiazide does not block beta receptors; this is the mechanism of action for beta-blockers.
D. Hydrochlorothiazide does not promote the movement of extravascular fluids into the vascular compartment; instead, it reduces blood volume by promoting diuresis.